


ILCA 2020 Virtual Industry Partner Symposium

How could treatment practice change with cancer immunotherapy combinations in patients with HCC?

Friday 11 September 2020

14.00–15.00 CET



Chair's Welcome

Dear Colleagues,

Over the course of the last 10 years, little progress has been made in the field of unresectable HCC. After relying on only tyrosine kinase inhibitors in first-line systemic therapy for over a decade, a number of trials of novel cancer immunotherapy combinations have shown improved outcomes for patients with HCC. These emerging positive clinical trial data have contributed to a rapidly evolving treatment landscape in unresectable HCC, with implications for clinical practice. We now need to optimise our clinical experience of monitoring and managing patients with HCC who are undergoing treatment with these combinations.

As such, we are delighted to present our Roche-sponsored industry symposium, ***“How could treatment practice change with cancer immunotherapy combinations in patients with HCC?”*** as part of the ILCA 2020 virtual programme.

In this symposium, our esteemed panel will give an overview of the evolving treatment landscape for HCC, review the most recent data for cancer immunotherapy combinations in patients with unresectable HCC and, crucially, provide expert insights and guidance on how their safety profiles can be navigated. With the ongoing expansion of the HCC armamentarium, we will also discuss what clinicians need to know in order to make informed and tailored treatment decisions for their patients.

We are excited to conclude our symposium with discussion of a patient case and an interactive Q&A session. Considering the broad attendance of ILCA, we invite you to participate in what is sure to be an engaging, meaningful and multidisciplinary dialogue!

On behalf of the faculty, I look forward to your contribution.

Yours sincerely,

Peter Galle

Agenda

	Presentation	Faculty
14.00–14.02	Welcome and introductions	Peter Galle
14.02–14.10	Navigating the shifting treatment patterns for HCC	Jian Zhou
14.10–14.20	Understanding the latest efficacy data for unresectable HCC	Peter Galle
14.20–14.35	Discussing safety with cancer immunotherapy combinations	Bruno Sangro
14.35–14.45	Making the correct clinical decisions: what do we need to know?	Riccardo Lencioni
14.45–15.00	Reviewing a patient case: who are the right patients for cancer immunotherapy combinations? Panel discussion and Q&A	All faculty

Guest Speakers



Symposium Chair:

Peter Galle

University Medical Centre Mainz, Germany

Peter Galle is Chief Physician of the Department of Gastroenterology and Hepatology at University Medical Centre Mainz, and has served as co-editor for the Journal of Hepatology. His research focuses on hepatic apoptotic cell death, immune escape of tumour cells, and clinical and molecular aspects of HCC. He is the current President of the German Association for the Study of the Liver (GASL).



Riccardo Lencioni

Miami Cancer Institute, USA

Riccardo Lencioni is an Honorary Research Professor of Interventional Oncology at the Miami Cancer Institute. He is a leading member of several expert panels and has co-authored numerous white papers. He is also an Associate Editor of Liver Cancer.



Bruno Sangro

Clínica Universidad de Navarra, Spain

Bruno Sangro is Director of the Liver Unit and Co-Director of the HPB Oncology Area at Clínica Universidad de Navarra. He is actively involved in research focused on therapeutic innovation in the field of liver cancer, and currently serves as President of ILCA.



Jian Zhou

Zhongshan Hospital, China

Jian Zhou is Director of the Liver Surgery & Transplantation department at Zhongshan Hospital, and has worked in the field of liver cancer for 29 years. He has been in charge of 23 research projects and has published 78 SCI papers as first or corresponding author. His research focuses on the early diagnosis, prevention and treatment of recurrence and metastasis of HCC.



Scan the QR code to submit
your questions to the faculty